No Data
Shionogi & Co. to Enhance Governance With New Audit and Supervisory Committee
Democrats Warn Trump About Consequences of HIV Prevention Cuts
Fanpep --- the administration of subjects has begun in the additional Phase III clinical trial of the functional peptide 'SR-0379'.
Fanpep Co., Ltd. <4881> announced on the 19th that it has started administering the clinical trial drug to the first subject in the additional Phase III clinical trial of the functional peptide SR-0379 (SR0379-JP-SU-02 trial, hereafter referred to as trial 02). SR-0379 is a peptide composed of 20 amino acids, possessing wound healing effects through promoting angiogenesis and granulation, as well as antibacterial activity. It is a spray formulation that can be stored at room temperature, and its use is expected for a wide range of patients with skin ulcers.
FRONTEO and Wealth Advisors are focusing on the AI program Medical Devices with Shionogi.
FRONTEO <2158.T> was noted in a report by Wealth Advisors on the 19th, regarding the focus on the life sciences AI sector within the AI (Artificial Intelligence) solution business. In this field, the "Conversational Cognitive Function Test AI Program Medical Device (SDS-881)" being co-developed with Shionogi & Co., Ltd. <4507.T> was just designated as a priority review item by the Ministry of Health, Labour and Welfare. The application for clinical trial approval has already been submitted to PMDA (Pharmaceuticals and Medical Devices Agency), and it is progressing smoothly.
List of cloud breakout stocks (Part 1) [Ichimoku Kinko Hyo - List of cloud breakout stocks].
○ List of stocks that break through the clouds Market Code Stock name Closing price Leading Span A Leading Span B Tokyo Stock Exchange Main Board <1332> Nissui 890 855.75 889 <1766> Tokken Corp 1241 012282.5 11825 <1951> Exeo Group 1751 1692.25 1739 <1979> Taikisha 4800 4698.75 4782.5 <1980> Dai-Dan 3755 370
Market Chatter: Ping An Insurance Exits JV With Shionogi